

# CITATION REPORT

List of articles citing

A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study

DOI: 10.1016/j.cct.2020.106170

Contemporary Clinical Trials, 2020, 98, 106170.

**Source:** <https://exaly.com/paper-pdf/75537757/citation-report.pdf>

**Version:** 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
47	Non-alcoholic fatty liver disease: digest 2021. <i>Russian Journal of Evidence-Based Gastroenterology</i> , <b>2021</b> , 10, 27	0.3	
46	Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis. <i>Drugs</i> , <b>2021</b> , 81, 419-443	12.1	2
45	Therapeutic approaches for non-alcoholic steatohepatitis. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , <b>2021</b> , 12, 20420188211034300	4.5	1
44	Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1069-1083	6.7	28
43	Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 615978	4.9	21
42	Pathophysiology and Treatment Options for Hepatic Fibrosis: Can It Be Completely Cured?. <i>Cells</i> , <b>2021</b> , 10,	7.9	9
41	Targeting cell-intrinsic metabolism for antifibrotic therapy. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1442-1454	13.4	4
40	Anti-diabetic drugs and NASH: from current options to promising perspectives. <i>Expert Opinion on Investigational Drugs</i> , <b>2021</b> , 30, 813-825	5.9	2
39	Saroglitazar, a PPAR- $\gamma$ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. <i>Hepatology</i> , <b>2021</b> , 74, 1809-1824	11.2	35
38	Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).. <i>Journal of Clinical and Translational Hepatology</i> , <b>2021</b> , 9, 939-946	5.2	0
37	Diet and exercise in NAFLD/NASH: Beyond the obvious. <i>Liver International</i> , <b>2021</b> , 41, 2249-2268	7.9	8
36	Saroglitazar for the Treatment of NASH: The Peroxisome Proliferator-Activated Receptor Story Goes On!. <i>Hepatology</i> , <b>2021</b> , 74, 1730-1733	11.2	2
35	Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 880-889	6.1	9
34	Inflammatory and fibrotic mechanisms in NAFLD-Implications for new treatment strategies. <i>Journal of Internal Medicine</i> , <b>2021</b> ,	10.8	6
33	Targeting Gut-Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension. <i>Livers</i> , <b>2021</b> , 1, 147-179		0
32	Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis. <i>Advanced Drug Delivery Reviews</i> , <b>2021</b> , 176, 113888	18.5	6
31	A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 1547-1558	59.2	50

30	The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD. <i>Oxidative Medicine and Cellular Longevity</i> , <b>2021</b> , 2021, 6889533	6.7	6
29	The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective. <i>Cells</i> , <b>2021</b> , 10,	7.9	1
28	Targeting monocytes/macrophages in fibrosis and cancer diseases: Therapeutic approaches. <i>Pharmacology &amp; Therapeutics</i> , <b>2021</b> , 108031	13.9	2
27	Pharmacology of NASH. <b>2021</b> ,		
26	The metabolic triad of NAFLD, visceral adiposity and type 2 diabetes: implications for treatment.. <i>Diabetes, Obesity and Metabolism</i> , <b>2022</b> ,	6.7	2
25	NAFLD and NASH: The Metabolically Diseased Liver. <i>Handbook of Experimental Pharmacology</i> , <b>2021</b> , 1	3.2	0
24	Nonalcoholic Steatohepatitis, Peroxisome Proliferator-Activated Receptors and Our Good Glitazar: Proof of the Pudding is in the Eating.. <i>Journal of Clinical and Experimental Hepatology</i> , <b>2022</b> , 12, 263-267 <sup>4.1</sup>		
23	The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease.. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	4
22	The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. <i>Terapevticheskii Arkhiv</i> , <b>2022</b> , 94, 216-253	0.9	5
21	Histological assessment based on liver biopsy: the value and challenges in NASH drug development.. <i>Acta Pharmacologica Sinica</i> , <b>2022</b> ,	8	0
20	Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis.. <i>Archives of Pharmacal Research</i> , <b>2022</b> , 1	6.1	0
19	Chronic Liver Diseases: From Development to Novel Pharmacological Therapies.. <i>British Journal of Pharmacology</i> , <b>2022</b> ,	8.6	
18	PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients.. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,	6.3	2
17	Update of Indoles: Promising molecules for ameliorating metabolic diseases.. <i>Biomedicine and Pharmacotherapy</i> , <b>2022</b> , 150, 112957	7.5	0
16	Macrophages as key regulators of liver health and disease. <i>International Review of Cell and Molecular Biology</i> , <b>2022</b> ,	6	1
15	Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis. <i>Hepatology Communications</i> ,	6	0
14	Circulating adiponectin in patients with nonalcoholic fatty liver disease-related liver fibrosis: a systematic review and a meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> ,	4	0
13	Integrated Bioinformatics Analysis Identifies Robust Biomarkers and Its Correlation With Immune Microenvironment in Nonalcoholic Fatty Liver Disease. <i>Frontiers in Genetics</i> , 13,	4.5	

12	Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23, 7841	6.3	4
11	Heterogeneous population of macrophages in the development of non-alcoholic fatty liver disease?. <i>Liver Research</i> , <b>2022</b> ,	4.1	
10	Therapies for non-alcoholic fatty liver disease: A 2022 update. 14, 1718-1729		0
9	Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis. <b>2022</b> , 18, 148		0
8	The Perspective of PPAR Dual/Pan Agonists as Therapeutic Drugs against NAFLD. <b>2022</b> , 142, 1335-1343		0
7	Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different. <b>2022</b> , 23, 16226		1
6	Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials. <b>2023</b> , 24, 158		0
5	Hepatic fibrosis: targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines. Publish Ahead of Print,		0
4	Metabolic-associated fatty liver disease: pharmacological management. <b>2023</b> , 319-341		0
3	X. Novel Therapies for Liver Cirrhosis: Development and Clinical Trial of Drugs and Regenerative Medicine. <b>2022</b> , 111, 74-81		0
2	Antioxidant and anti-inflammatory agents in chronic liver diseases: Molecular mechanisms and therapy. 15, 180-200		1
1	From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications. <b>2023</b> , 11, 883		0